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Thrombin-Induced Changes in Platelet Membrane Glycoproteins
Ib, IX, and lib-Illa Complex
By Alan D. Michelson and Marc R. Barnard
Platelet membrane glycoprotein lb (GPIb) and the GPllb-llla
complex have central roles in the interaction of platelets
with the plasma coagulation system. damaged vessel walls.
and other platelets. We investigated the effects of throm-
bin on these glycoproteins. Monoclonal antibodies were
used to assess platelet surface glycoproteins by flow
cytometry. total platelet glycoprotein content by immu-
noassay. and glycoproteins released from platelets. also by
immunoassay. Five new observations were made with
regard to thrombin-induced changes in platelet membrane
glycoproteins: (a) The marked decrease in platelet surface
binding of antibodies directed at GPIb was not confined to
antibodies directed at the von Willebrand factor binding
P LATELET MEMBRANE GLYCOPROTEIN (GP)Ib
and the GPIIb-IIIa complex have central roles in the
interaction of platelets with the plasma coagulation system,
with damaged blood vessel walls, and with other platelets.’
First, the glycocalicin portion of the a chain of GPIb contains
a binding site(s) for thrombin.23 Second, platelet adhesion to
damaged blood vessel walls is mediated by the binding of the
adhesive glycoprotein von Willebrand factor (vWf) to the
glycocalicin portion of the a chain of platelet membrane
GPIb.’45 Third, platelet aggregation is mediated by the
activation-dependent binding of several adhesive glycopro-
teins, including fibrinogen, fibronectin, and vWf, to the
platelet membrane GPIIb-IIIa complex.’5
Thrombin-induced changes in GPIb and the GPIIb-IIIa
complex may be important in modulating the reactivity of
platelets with the damaged vessel wall and with other
platelets. George et a19 recently demonstrated that thrombin
activation of platelets results in decreased binding of a
monoclonal antibody directed at the vWf binding site on
GPIb. A number of investigators have observed a thrombin-
induced increase in the platelet surface expression of the
GPIIb-IIIa complex.9”
In unactivated platelets, platelet membrane GPIX is
bound to platelet surface GPIb in a I : 1 ratio (the GPIb-lX
complex).’3”4 However, the function ofGPIX is unknown. In
addition to their platelet surface pools, GPIb and the GPHb-
lila complex are present in intraplatelet pools)o”,’5
In the present study, a library of monoclonal antibodies
was used to investigate thrombin-induced changes in GPIb,
GPIX, and the GPIIb-IIIa complex. Different pools of these
glycoproteins were assessed by the following techniques: (a)
platelet surface glycoproteins by flow cytometry,’6”7 (b)
glycoproteins released from platelets by enzyme-linked
immunosorbent assay (ELISA),5”8 and (c) total platelet
glycoprotein content by ELISA of Triton X-lOO platelet
lysates.
MATERIALS AND METHODS
Antibodies. Table 1 lists the eight murine monoclonal antibod-
ies used in this study. We used three different antibodies (6D1,
WM23, and 3G6) directed against the glycocalicin portion of the a
chain of platelet membrane GPIb. Antibody 6Dl is directed at or
very near the vWf binding site on GPIb,4 whereas WM23 and 3G6
are not directed against the vWf binding site (Berndt et al” and B.
site. (b) There was a marked decrease in platelet surface
binding of an antibody directed at GPIX. with maintenance
of the 1 :1 ratio of platelet surface binding of antibodies
directed at GPlb and GPIX. (c) Changes in platelet surface
binding of antibodies were not restricted to a distinct
subpopulation of platelets. (d) There was no associated
platelet release of glycocalicin (a proteolytic fragment of
GPIb). (a) There was no associated platelet release of the
GPllb-lIla complex. These thrombin-induced changes may
be important in modulating the reactivity of platelets with
the damaged vessel wall and with each other.
0 1987 by Grune & Stratton. Inc.
Adelman, personal communication). WM23 has been characterized
as being directed against the macroglycopeptide portion of glycocali-
cm rather than the terminal protein portion that contains the vWf
and 6D1 binding sites (MC. Berndt, personal communication).
After complete platelet solubilization with sodium dodecyl sulfate,
polyacrylamide gel electrophoresis and Western blotting, both 3G6
(B. Adelman, personal communication) and WM23 (MC. Berndt,
personal communication) recognize only a single band (GPIb) in
both reduced and unreduced gels. FMC25 is directed against
platelet membrane GPIX.”9 Antibody 10E5 is directed against the
platelet membrane GPIIb-IIIa complex.#{176}WM I 8 is also directed
against the platelet membrane GPIIb-IIIa complex but at a different
epitope to 10E5 because WM18 has little effect on platelet aggrega-
tion (MC. Berndt, personal communication), whereas lOE5 inhibits
platelet aggregation induced by adenosine diphosphate (ADP),
epinephrine, and collagen.’#{176}As a marker of platelet activation, we
used KC4, a monoclonal antibody directed against the platelet
activation-dependent granule-external membrane (PADGEM)
protein.2”22 PADGEM protein is a component of the a granule
membrane of resting platelets that is expressed on the platelet
plasma membrane during platelet activation.22 PADGEM protein is
distinct from the surface glycoproteins of resting platelets but
identical to GMP-140, the antigen recognized by monoclonal anti-
body S I 2.’ As a control in the flow cytometric assay, we used
0X6, a monoclonal antibody directed against rat lymphocyte Ia
antigen.24
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Table 1 . Monoclon& Antibodies Used in This Study
Antibody Antigen Sotwce
6D 1 Human platelet membrane GPIb (vWf
binding site on glycocalicin)
WM23 Human platelet membrane GPlb
(macroglycopeptide portion of gly-
cocalicin; not the vWf binding site)
3G6 Human platelet membrane GPlb (gly-
cocalicin; not the vWf binding site)
FMC25 Human platelet membrane GPIX
10E5 Human platelet membrane GPIIb-llla
complex (inhibits platelet agega-
tion induced by ADP. epinephrine,
collagen)
WM 18 Human platelet membrane GPllb-llIa
complex (little effect on platelet ag-
egation)
KC4 Human PADGEM protein
OX6 Rat lymphocyte Ia antigen
Dr Barry Coller
Dr Michael Berndt
Dr Burt Adelman
Dr Michael Berndt
Dr Barry Coller
Dr Michael Berndt
Dr Bruce Furie
Dr Bruce Woda
For references, see Materials and Methods.
Thrombin activation of washed platelets. Blood was drawn by
venipuncture from healthy adult volunteers who had not ingested
aspirin within the previous ten days. The blood was drawn directly
into a syringe containing ‘/i vol of acid-citrate-dextrose (85 mmol/L
trisodium citrate, 71 mmol/L citric acid, I 1 1 mmol/L dextrose, pH
4.5) and 50 ng/mL (final concentration) prostaglandin E, (PGE,,
Sigma Chemical Co. St Louis). After resting for one hour at 22#{176}C,
the blood was centrifuged at 150 g for 15 minutes at 22#{176}Cand the
platelet-rich plasma removed. The platelets were washed twice by
centrifugation at 2,000 g for ten minutes at 22#{176}Cand resuspension in
Tyrode’s buffer (138 mmol/L NaCI, 29 mmol/L KC1, 12 mmol/L
NaHCO3, 0.4 mmol/L NaHPO4, 0.1% glucose, 0.35% bovine serum
albumin, pH 6.5) with 50 ng/mL PGE,. After the second wash, 5 x
l0 platelets/iiL were suspended in Tyrode’s buffer, pH 7.3, with 50
ng/mL PGE, and either 5 mmol/L EDTA or 2 mmol/L CaC12.
Purified human a-thrombin (generously provided by Dr John Fen-
ton II, New York Department of Health, Albany) at concentrations
between 6.4 x i0, and 1.0 U/b8 platelets was added to the
sample, which was then gently inverted once. In control assays
performed in parallel, buffer only (no thrombin) was added. The
samples were incubated undisturbed (to prevent platelet aggrega-
tion) for ten minutes at 37#{176}C.To stop the reaction, hirudin (Sigma),
2.0 U/b8 platelets, was added to all samples, including those with
no thrombin. After gentle inversion, the samples were incubated at
22#{176}Cfor five minutes. Each sample was then divided into two
separate aliquots. The first aliquot was fixed at 22#{176}Cfor 30 minutes
with an equal volume of 2% formaldehyde in Tyrode’s buffer, pH
7.3, with either 5 mmol/L EDTA or 2 mmol/L CaC12. These
samples were then washed twice in Tris-buffered saline (10 mmol/L
Tris-HCI, 0.15 mol/L NaCI, pH 7.8) by centrifugation at 2,000 g
for ten minutes at 22#{176}C,resuspended at 50,000 platelets/sL in
Tris-buffered saline, and assayed by flow cytometry for platelet
surface glycoproteins (see the next section). The second aliquot of
thrombin-activated and control platelets was centrifuged at 2,000 g
for ten minutes at 22#{176}C.The supernatants were removed for ELISA
determination of platelet release of glycocalicin (a proteolytic frag-
ment of GPIb) and the GPIIb-IIIa complex (see later). The platelet
pellets were lysed in Tyrode’s buffer containing 1% Triton X-I00
(Sigma), SOng/mL PGE,, and either 5 mmol/L EDTA or 2 mmol/L
CaCI2. Before being assayed, the supernatants and lysates were
stored at - 80#{176}Cfor up to seven days. Before assay by ELISA for the
total platelet content of GPIb and the GPIIb-IIIa complex (see
later), the lysates were thawed and, to remove any cellular debris,
centrifuged at 22#{176}Cfor four minutes at 8,000 g (conditions that
result in only a small degree of sedimentation of actin filament-
associated GPIb).
Flow cytometric assessment of platelet surface glycopro-
teins. Fixed, washed thrombin-activated and control platelets
(50,000/giL) were prepared as described earlier and incubated for
20 minutes at 22#{176}Cwith a saturating concentration of one of five
monoclonal antibodies (6D1, WM23, 3G6, FMC25, or 10E5) to
assess platelet surface glycoproteins. In parallel experiments, ali-
quota of these platelet suspensions were incubated with either
monoclonal antibody KC4 or monoclonal antibody OX6 to assess
platelet activation and background binding, respectively. As
described by George et a19 the platelet surface GPIIb-IIIa complex
was assessed on platelets activated in a Ca k-containing buffer,
whereas the platelet surface GPIb-IX complex was assessed on
platelets activated in an EDTA-containing buffer. Thus, the platelet
samples that had been prepared in the presence of 2 mmol/L CaCl2
(see earlier) were incubated with either 10E5 or 0X6, whereas the
platelet samples that had been prepared in the presence of 5 mmol/L
EDTA were incubated with either 6D1, WM23, 3G6, FMC25, or
OX6. Platelet surface expression of PADGEM protein was assessed
by antibody KC4 on platelets prepared in the Ca-containing
buffer. All platelet samples were then washed twice in Tris-buffered
saline by centrifugation at 2,000 g for ten minutes at 22#{176}Cand
incubated for 20 minutes at 22#{176}Cwith a saturating concentration of
fluorescein isothiocyanate-labeled goat antimouse IgG antibody
(Cooper Biomedical, Malvern, PA). The platelets were then washed
twice, resuspended in Tris-buffered saline, and analyzed in a FACS
440 (Becton Dickinson, Mountain View, CA). For each sample, the
fluorescence signal from 10,000 individual cells was measured.
Forward-light scatter profiles indicated that there was neither
platelet clumping nor detectable contamination by other cell types in
any of the samples. Histograms were gated for platelets by their
characteristic forward and orthogonal light scatter, thereby exclud-
ing any possible contribution from other cells or debris. To compare
results in linear form, data obtained from fluorescence channels in a
logarithmic mode were converted to their linear equivalents (relative
specific fluorescence) as previously described.’7
ELISA determination ofplatelet release ofglycocalicin and the
GPIIb-JJJa complex. Supernatants obtained from centrifugation
of thrombin-activated and control platelets were assessed for their
glycocalicin content by an ELISA using monoclonal antibody 6D1
as previously described.5”5 In parallel assays, 6D1 was replaced by
either monoclonal antibody 10E5 or monoclonal antibody WMI8.
As described earlier, the supernatants used for assays with 6D1 were
EDTA-containing, whereas the supernatants used for assays with
10E5 and WM18 were Ca-containing.
ELISA determination of total platelet content of GPIb and the
GPJIb-JJIa complex. Lysates obtained after Triton X-100 solubili-
zation of thrombin-activated and control platelets were assessed in
the ELISA for their ability to inhibit monoclonal antibody 6D1
binding to platelet surface GPIb. This assay measures the total
number of GPIb receptors for vWf because 6D1 binds with equal
avidity to GPIb and glycocalicin.5 The assay was validated by
demonstrating a comparable total number of GPIb molecules per
platelet in experiments in which the monoclonal antibody to GPIb
was changed from 6D1 to WM23 or 3G6 and in other experiments in
which, rather than Triton X-100 platelet lysates, the aqueous phase
of Triton X-114-solubilized platele&’ was assessed (A.D. Michel-
son, M.R. Barnard, E. Carroll: unpublished observations). Serial
dilutions of the lysates obtained after Triton X-100 solubilization of
thrombin-activated and control platelets were also assessed in the
ELISA for their ability to inhibit the binding of either monoclonal
antibody 10E5 or monoclonal antibody WM18 to the platelet
surface. As described earlier, the lysates used for assays with 6D1
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(U/ i0 platelets)
were EDTA-containing, whereas the lysates used for assays with
lOE5 and WMI8 were Ca-containing. Control assays in which
platelets were replaced by buffer only and then treated with 1%
Triton X-lOO resulted in the detection of no GPIb (n - 3) or
GPIIb-IIIa complex (n = 3), thereby demonstrating that the dilu-
tions of Triton used did not interfere with the ELISA.
Platelet counts. Platelet counting was performed on a Coulter
Model ZBI (Coulter Electronics, Hialeah, FL).
RESULTS
A flow cytometric method was used to demonstrate the
effect of thrombin on platelet surface glycoproteins. As
shown in Fig I , thrombin resulted in a marked reduction in
the platelet surface binding of each of three monoclonal
antibodies (6D1, WM23, and 3G6) directed against dif-
ferent epitopes on GPIb (Table 1). In addition, thrombin
resulted in a similar reduction in the platelet surface binding
of a monoclonal antibody (FMC25) directed against GPIX
(Fig 1). In contrast, thrombin resulted in a marked increase
in the platelet surface binding of a monoclonal antibody
(lOE5) directed against the GPIIb-IIIa complex (Fig 1).
Parallel assays using monoclonal antibody KC4 (directed
against PADGEM protein) demonstrated that the thrombin-
induced changes in the platelet surface binding of mono-
clonal antibodies directed against GPIb, GPIX, and the
Fig 1 . Effect of thrombin on the binding
of monoclonal antibodies to the platelet sur-
face as determined by flow cytometry. Plate-
lets were incubated with monoclonal anti-
bodies directed against either GPlb (6D1.
WM23. and 3G6). GPIX (FMC25). the GPllb-
lIla complex (10E5). or PADGEM protein
(KC4). All samples were then incubated with
fluoresceinated goat antimouse antibody. For
each antigen. the relative specific fluores-
cence of control platelets was arbitrarily
assigned 1 00 units.
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GPIIb-IIIa complex were associated with platelet activation
(Fig I).
As determined by relative specific fluorescence, in unacti-
vated platelets the ratio of platelet surface binding of
6Dl:FMC25:10E5 (monoclonal antibodies directed at GPIb,
GPIX, and the GPIIb-IIIa complex, respectively) was
1 .0:0.9:2.0 (means of five separate experiments). These
ratios are comparable to the ratio of platelet surface
GPIb:GPIX:GPIIb-IIIa complex reported by other investi-
gators using radioligand binding methods.”3”4 In maximally
activated platelets (thrombin, 1 .0 U/108 platelets), the ratio
of platelet surface binding of 6D1:FMC25:lOE5 was
1 .0:0.9:29.1 (means of five separate experiments). Similarly,
despite the thrombin-induced changes, there was mainte-
nance of the approximately 1 :1 ratio of the platelet surface
binding of 6D1:FMC25 at all concentrations of thrombin
tested (Figs 1 and 2).
The flow cytometric method of analyzing platelet surface
glycoproteins is able to detect distinct subpopulations of
platelets because each platelet is analyzed individually.’6”7
However, the thrombin-induced changes in binding of mono-
clonal antibodies to platelet surface GPIb, GPIX, and the
GPIIb-IIIa complex were not restricted to a distinct subpop-
ulation of platelets, irrespective of whether the thrombin
concentration resulted in partial or complete activation of
THROMBtN CONCENTRATION
1 GPIIb-IIIa
J complex
l GPIb-IXJ complex
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#{149}Determined from 1 % Triton X- 100 lysates of platelets.
tDetermined from supernatants.
Fig 2. Effect of different
concentrations of thrombin on
the binding of monoclonal anti-
bodies to the platelet surface
as determined by flow cytome-
try. The solid lines represent
platelets activated with the
indicated concentrations of
thrombin and then incubated
with the indicated primary
monoclonal antibody. The
dashed lines represent plate-
lets incubated with an irrele-
vant primary monoclonal anti-
body (background). All samples
were then incubated with a flu-
oresceinated goat antimouse
antibody. For each panel. the
x-axis represents log fluores-
cence. and the y-axis repre-
sents cell number.
platelets (Fig 2). This is demonstrated in Fig 2 by the fact
that, for all antibodies tested, increasing concentrations of
thrombin resulted in a gradual shift of a single peak (to the
left for the GPIb-IX complex, to the right for the GPIIb-IHa
complex).
For both control and maximally thrombin-activated plate-
lets, the total platelet GPIb content and glycocalicin released
from platelets were determined by ELISA using antibody
6D1. As shown in the upper portion of Table 2, the total
platelet content of GPIb did not change significantly after
activation with thrombin, 1.0 U/108 platelets. As shown in
the lower portion of Table 2, the glycocalicin released from
platelets was, as expected, very low in the control and did not
rise appreciably in the thrombin-activated platelets.
For both control and maximally thrombin-activated plate-
Table 2. Effect of Thrombin (1 .0 U/10 Platelets) on the Total
Platelet GPIb Content and Release of Glycocalicin as
Determined by ELISA Using Monoclonal Antibody 6D1
Percentage of Total GPIb Content
of Control Platelets
Parameter (Mean ± SEM, n - 6)
Total platelet GPlb content
Control platelets 100.0 ± 18.4
Thrombin-activated platelets 97.4 ± 18.7
Glycocalicin released from plate-
letsf
Control platelets 0.3 ± 0.05
Thrombin-activated platelets 0.9 ± 0.1
lets, the total platelet content and platelet release of the
GPIIb-IIIa complex were determined by ELISA using anti-
body 10E5. As shown in Fig 3, the total platelet content of
the GPIIb-IIIa complex did not change significantly after
activation with thrombin, 1 .0 U/ 108 platelets. Likewise, the
platelet release of the GPIIb-IIla complex was very low in
the control and did not rise significantly in the thrombin-
activated platelets (Fig 3). In parallel assays using antibody
WM18, there was similarly no thrombin-induced change in
the total platelet content of the GPIIb-IIIa complex and no
release of the GPIIb-IIIa complex from platelets (data not
shown).
DISCUSSION
In this study, the effects of thrombin on platelet mem-
brane GPIb, GPIX, and the GPIIb-IIla complex were inves-
tigated. Five new observations were made.
First, the thrombin-induced change in the glycocalicin
portion of the a chain of platelet surface GPIb was not
confined to its vWf binding site. In addition to the previously
reported9 thrombin-induced marked decrease in binding of a
monoclonal antibody directed at the vWf binding site on
GPIb, we observed a comparable marked decrease in the
binding of two other monoclonal antibodies directed at
different epitopes on the glycocalicin portion of the a chain of
GPIb. The thrombin-induced decrease in binding of mono-
clonal antibodies directed at GPIb was not due to occupation
ofthe antibody binding site by thrombin bound to its receptor
on GPIb’3 because (a) three monoclonal antibodies (6D1,
WM23, and 3G6) directed against different epitopes on
 For personal use only. at UNIV OF MASSACHUSETTS on April 3, 2008. www.bloodjournal.orgFrom 
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Fig 3. Effect of thrombin (1 .0 U/10 platelets) on the total
platelet content and release of the GPllb-llla complex as deter-
mined by ELISA using monoclonal antibody 1 0E5. The total platelet
content of the GPllb-llla complex was determined from 1 % Triton
x-1 00 lysates of control platelets (open circles, C lysate) and
thrombin-activated platelets (closed circles, T lysate). Platelet
release of the GPIIb-llIa complex was determined from superna-
tants of control platelets (open triangles. C supernatant) and
thrombin-activated platelets (closed triangles. T supernatant).
Results are means ± SEM. n - 3.
GPIb produced similar results and (b) monoclonal antibody
6D1 does not interfere with the binding of thrombin to
platelets.2
Second, we observed a thrombin-induced marked decrease
in the binding of a monoclonal antibody directed at GPIX.
Although the function of GPIX is presently unknown, our
data suggest the possibility that GPIX has a role in platelet
activation. It has previously been demonstrated in unacti-
vated platelets that surface GPIb is bound to GPIX in a 1:1
ratio (the GPIb-IX complex).’3”4 The present data suggest
that during the thrombin-induced changes in platelet surface
GPIb and GPIX there is maintenance of this 1 :1 ratio.
Third, the flow cytometric method enabled us to deter-
mine that the thrombin-induced changes in the binding of
mononclonal antibodies to GPIb, GPIX, and the GPIIb-HIa
complex were not restricted to a distinct subpopulation of
platelets. Radioligand binding studies such as those used by
George et a19 are unable to make this distinction because the
results are averaged measurements of large numbers of
platelets. In contrast, because each platelet is analyzed
individually, flow cytometry is able to detect distinct subpop-
ulations of platelets, as we have recently demonstrated in
children with chronic myeloid leukemia.’7
Fourth, despite the thrombin-induced marked decrease in
binding of monoclonal antibody 6D1 to platelet surface
GPIb, quantitative ELISA (performed in parallel and using
the same monoclonal antibody) revealed no significant
thrombin-induced release of glycocalicin from the platelet
and no change in the total platelet content of GPIb. In view
of our previous finding that proteolytic cleavage of glycocali-
cm does not interfere with its measurement by our ELISA,’8
the direct measurement of released glycocalicin in the pres-
ent study demonstrated that the thrombin-induced marked
decrease in the platelet binding of anti-GPIb monoclonal
antibodies was not the result of cleavage of platelet surface
GPIb. The present study together with previous studies by
other investigators27’28 suggests that platelet surface GPIb is
still present on the platelet surface after thrombin activation
but its accessibility to multiple probes is greatly decreased
because of either (a) the marked clustering of GPIb mole-
cules that occurs on the platelet surface after thrombin
activation29; (b) the marked shape change that occurs in
platelets during thrombin activation (less likely because of
the associated increased accessibility of surface GPIIb-IIIa
complex); or (c) a major conformational change in the
GPIb-IX complex (also less likely because such a change
would not be expected to result in the same decrease in
binding of four monoclonal antibodies [6D1, WM23, 3G6,
and FMC25] directed at different epitopes on the GPIb-IX
complex and three of these antibodies [WM23, 3G6, and
FMC25] recognize their epitope on Western blots, which
suggests that they are relatively insensitive to conformational
changes in the antigen).
Fifth, unlike a granule constituents such as platelet factor
4 and fl-thromboglobulin,#{176} the GPIIb-IIla complex was not
released from platelets during thrombin activation. Although
the present investigation did not directly exclude the possibil-
ity that uncomplexed GPIIb and/or GPIIIa subunits were
released from platelets during thrombin activation, the lack
of change in the total platelet content of the GPIIb-IIIa
complex, as determined by two different complex-specific
monoclonal antibodies, did not support this view.
In conclusion, given the central roles of GPIb and the
GPIIb-IIIa complex in platelet adhesion and aggregation,’
the presently described thrombin-induced changes in these
glycoproteins are likely to be important in modulating the
reactivity of platelets with the damaged blood vessel wall and
with other platelets.
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